This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
m5C regulator-mediated methylation modification phenotypes characterized by distinct tumor microenvironment immune heterogenicity in colorectal cancer
Scientific Reports Open Access 24 July 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Lenz, H. J. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J. Clin. Oncol. https://doi.org/10.1200/JCO.21.01015 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. MSI-H/dMMR mCRC: ICIs in the first line?. Nat Rev Clin Oncol 18, 748 (2021). https://doi.org/10.1038/s41571-021-00576-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00576-z